Why the study?
Are genetic variants in adenosine receptor genes associated with infarct size in patients with ischemic cardiomyopathy?
Are genetic variants in adenosine receptor genes associated with infarct size in patients with ischemic cardiomyopathy?
Specific polymorphisms in adenosine receptor genes are associated with altered infarct size in patients with ischemic cardiomyopathy, suggesting a genetic basis for individual responses to ischemia.
May refine infarct risk stratification in ischemic cardiomyopathy; hypothesis-generating and requires prospective validation.
The goal of this experiment was to identify the presence of genetic variants in the adenosine receptor genes and assess their relationship to infarct size in a population of patients with ischemic cardiomyopathy. Adenosine receptors play an important role in protecting the heart during ischemia and in mediating the effects of ischemic preconditioning. We sequenced DNA samples from 273 individuals with ischemic cardiomyopathy and from 203 normal controls to identify the presence of genetic variants in the adenosine receptor genes. Subsequently, we analyzed the relationship between the identified genetic variants and infarct size, left ventricular size, and left ventricular function. Three variants in the 3'-untranslated region of the A(1)-adenosine gene (nt 1689 C/A, nt 2206 Tdel, nt 2683del36) and an informative polymorphism in the coding region of the A3-adenosine gene (nt 1509 A/C I248L) were associated with changes in infarct size. These results suggest that genetic variants in the adenosine receptor genes may predict the heart's response to ischemia or injury and might also influence an individual's response to adenosine therapy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: